# Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms

> **NCT05316480** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 42 (estimated)

## Conditions studied

- Pancreatic Neuroendocrine Neoplasm

## Interventions

- **DRUG:** Nimotuzumab

## Key facts

- **NCT ID:** NCT05316480
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-05-01
- **Primary completion:** 2025-04-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2022-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05316480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05316480, "Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05316480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*